Objectives Despite the rapid proliferation of robot-assisted radical prostatectomy (RARP), little attention has been paid to patient utilisation of this newest surgical innovation and barriers that may result in disparities in access to RARP. The goal of this study is to identify demographic and economic factors that decrease the likelihood of patients with prostate cancer (PC) receiving RARP.
Design, setting and participants A retrospective, pooled, cross-sectional study was conducted using 2009–2011 California State Inpatient Data and American Hospital Association data. Patients who were diagnosed with PC and underwent radical prostatectomy (RP) from 225 hospitals in California were identified, using ICD-9-CM diagnosis and procedure codes.
Primary outcome measures Patients’ likelihood of receiving RARP was associated with patient and hospital characteristics using the two models: (1) between-hospital and (2) within-hospital models. Multivariate binomial logistic regression was used for both models. The first model predicted patient access to RARP-performing hospitals versus non-RARP-performing hospitals, after adjusting for patient and hospital-level covariates (between-hospital variation). The second model examined the likelihood of patients receiving RARP within RARP-performing hospitals (within-hospital variation).
Results Among 20 411 patients who received RP, 13 750 (67.4%) received RARP, while 6661 (32.6%) received non-RARP. This study found significant differences in access to RARP-performing hospitals when race/ethnicity, income and insurance status were compared, after controlling for selected confounding factors (all p<0.001). For example, Hispanic, Medicare and Medicaid patients were more likely to be treated at non-RARP-performing hospitals versus RARP-performing hospitals. Within RARP-performing hospitals, Medicaid patients had 58% lower odds of receiving RARP versus non-RARP (adjusted OR 0.42, p<0.001). However, there were no significant differences by race/ethnicity or income within RARP-performing hospitals.
Conclusions Significant differences exist by race/ethnicity and payer status in accessing RARP-performing hospitals. Furthermore, payer status continues to be an important predictor of receiving RARP within RARP-performing hospitals.
- HEALTH SERVICES ADMINISTRATION & MANAGEMENT
- Prostate disease < UROLOGY
This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Strengths and limitations of this study
The study captured both supply factors (hospital capability of performing robotic surgery) and demand factors (patient demographic and economic characteristics) that may have differential impacts on the utilisation of robot-assisted radical prostatectomies, which were not previously examined.
The study used a comprehensive database containing all inpatient records in the State of California (USA) from 2009 to 2011. However, these study results should be generalised with caution for other states within the USA or other countries.
This study used a cross-sectional design, and lacked clinical history and biomarker data on patients undergoing radical prostatectomies.
Robot-assisted radical prostatectomy (RARP) has been widely accepted by the urological society for the past 15 years. From 2005 to 2008, the number of RARPs increased from 9000 to 58 000.1 In 2010, it was estimated that 69–85% of all radical prostatectomy (RP) cases in the USA were performed robotically.2 Robotic surgery has the potential to improve processes and patient outcomes by helping younger novice surgeons learn to perform minimally invasive RP within a relatively short period of time.3 Research suggests that robotic surgery may improve patient outcomes, such as reduced blood loss, shorter length of hospital stay, lower risk of mortality, lower surgical complications, and faster recovery.4–8 Thus, this advanced surgical technology (ie, RARP) has been widely utilised in US healthcare, in spite of its higher costs, compared with open RP (ORP) and conventional laparoscopic RP (LRP).8
Racial and socioeconomic disparities have been well documented in the field of prostate cancer (PC) management/treatment.9–12 To the best of our knowledge, however, only one study has examined racial and socioeconomic disparities in access to an RARP-performing hospital.13 The previous study was conducted in between-hospital comparison, by examining RP patients’ access to hospitals with robotic technology versus hospitals without robotic technology. This is a legitimate approach because RARP is a highly equipment-intensive procedure, meaning that patients will not undergo RARP if they do not have access to the hospitals with robotic technology. Several studies have confirmed that the use of RARP is centralised within a few large, primarily academic, hospitals that are located in urban areas where racial and socioeconomic minorities have less access to those facilities.14–16 Thus, we conducted between-hospital analysis to identify demographic and economic factors that influence patients’ access to RARP-performing hospitals using all inpatient data relating to California.
However, patients with access to hospitals that have robotic technology may undergo different options of surgical treatment, including ORP, LRP and RARP. Current studies have not addressed whether the racial and socioeconomic differences exist in the use of RARP once the hospital-level access barrier is removed. Therefore, we extended current research by also examining within-hospital differences in the receipt of RARP versus non-RARP. Furthermore, we examined other patient-level characteristics, such as payer type, that may be important predictors of the receipt of RARP. Our study used a comprehensive database containing nearly all inpatient records for the State of California in order to assess whether there were systematic, between-hospital differences as well as within-hospital differences by race/ethnicity and socioeconomic status in patients’ access to RARP.
Materials and methods
We used the 2009–2011 California State Inpatient Database (SID) and the 2009 American Hospital Association Annual Survey Database. The SID is a component of the Healthcare Cost and Utilization Project sponsored by the Agency for Healthcare Research and Quality, and provides comprehensive data on hospital inpatient stays in each state.17 The AHA Annual Survey Database is a comprehensive hospital database of over 6500 hospitals in the USA and contains up to 1000 fields of information, including facility size, teaching status, service lines, inpatient and outpatient utilisation, and expenses.18
The study population included all patients who received RP for PC from 2009 to 2011 in California. To determine our analytic cohort, we first identified patients who had a primary diagnostic International Classification of Disease, 9th revision, Clinical Modification (ICD-9-CM) code for PC (185). We then identified patients with a primary procedure code for RP (60.5) and secondary procedure codes for any type of robotic intervention (17.41, 17.42, 17.43, 17.44, 17.45 and 17.49). To identify hospital characteristics, the California SID was merged with the 2009 AHA database. This approach identified 20 411 patients who were diagnosed with PC and who received RP in 225 hospitals in California for the study period 2009–2011. Of these, 18 101 patients had non-missing information on age, race/ethnicity, primary payer, patients’ place of residence and median ZIP code income.
We used two dependent variables: (1) a hospital-level binary variable of RARP-performing versus non-RARP-performing and (2) an individual-level binary variable of receiving or not receiving RARP. Thus, the first model examines availability of RARP across hospitals, and the second model examines determinants of patient receipt of RARP within RARP-performing hospitals.
Patient and hospital characteristics
Patient demographic information included age, race/ethnicity, primary payer, patients’ place of residence (metro vs non-metro), and median ZIP code income by quartile. Age was categorised as one of four groups: younger than 55, 55–64, 65–74, and 75 years and older. Race/ethnicity was categorised as non-Hispanic white, black or African-American, Hispanic and other (Asian or Pacific Islander, Native American and other). The patients’ primary payer was grouped into four main categories: private insurance, Medicare, Medicaid, and other (self-pay, no charge, worker's compensation, or other government and/or county indigent programmes). We used the 2003 version of the Rural-Urban Continuum Codes to classify metro and non-metro areas. Metro areas were defined as counties in metropolitan areas with the size of 1 million people or more, 250 000 to 1 million people, and below 250 000. Non-metro areas were defined as counties with urban population of 20 000 or more, 2500–19 999, and completely rural areas or less than 2500 urban populations. Median household income based on patient's ZIP code was separated into four quartiles. Quartiles were identified by values of 1 (the lowest quartile) to 4 (the highest quartile), indicating the poorest to wealthiest populations, respectively. The cut-offs for the quartile designation are determined using ZIP code demographic data obtained from Claritas.19
The study also included the Elixhauser comorbidity index, consisting of 29 coexisting medical conditions.20 Medical conditions were coded 1 if the comorbidity was present, or 0 if not present. We used the sum of all the comorbidity measures for the analysis. The three categories were added in the model: 0 (zero) comorbidities, 1 comorbidity and 2 or more comorbidities.
Three hospital characteristics were selected and added to the model based on previous studies.4 ,13 Ownership status was divided into three groups: for-profit (investor-owned), not-for-profit (religious or non-religious not-for-profit) and public/government (federal-owned or state/county-owned hospitals). Hospital teaching status (teaching and non-teaching) and bed size (0–399 and 400 or more beds) were also added to the model.
We obtained descriptive statistics of patient and hospital characteristics among all hospitals and for RARP-performing hospitals. Pearson's χ2 test was used to examine associations across different subgroups. This analysis was followed by multivariate logistic regression analyses examining whether patient and hospital characteristics were associated with (1) adjusted odds of accessing a RARP-performing hospital, and (2) adjusted odds of patients with PC receiving RARP within an RARP-performing hospital. A p value <0.05 denoted statistical significance. SAS V.9.3 was used to perform all statistical analyses.
Table 1 summarises 20 411 RP patient and hospital characteristics by RARP-performing versus non-RARP-performing hospitals. The number and trend of RARP cases during the study period are illustrated in the online supplementary table S1. Among 225 hospitals that performed at least one RP during the 3-year study period, 73 performed RARP and 152 did not perform RARP. RARP-performing hospitals had a higher proportion of patients who were non-Hispanic whites (71.0% vs 57.7%, p<0.001), private payers (62.5% vs 53.7%, p<0.001), and resided in the highest ZIP code income areas (37.3% vs 23.5%, p<0.001). More RP patients in RARP-performing hospitals had zero comorbidities (40.3% vs 32.7%, p<0.001) and lived in metro areas (97.8% vs 96.4%, p<0.001) compared with RP patients in non-RARP-performing hospitals. RARP-performing hospitals were more likely to have not-for-profit ownership (71.2% vs 60.9%, p=0.01), larger bed size (30.1% vs 5.3%, p<0.001) and teaching status (20.5% vs 3.3%, p<0.001).
Table 2 summarises 16 421 RP patient characteristics by receipt of RARP versus receipt of non-RARP within the 73 RARP-performing hospitals. No significant between-group differences were found by age (p=0.15), race/ethnicity (p=0.36), median household income (p=0.80), Elixhauser comorbidity index (p=0.36) or metro/non-metro category (p=0.78). However, significant differences were found by insurance status between patients who did versus those who did not receive RARP (63.1% vs 59.8% for private insurance; 1.4% vs 2.7% for Medicaid, respectively; p<0.001).
Table 3 shows results from the multivariate logistic regression analysis for both models. Model 1 examined the association of patient and hospital characteristics and the likelihood of accessing an RARP-performing hospital. The final sample for model 1 included 18 101 RP patients from 225 hospitals in California during the 3-year time period. Patients’ race/ethnicity, socioeconomic status and payer type were associated with the likelihood of accessing an RARP-performing hospital, after adjusting for selected confounding factors. More specifically, Hispanics (adjusted OR (AOR) 0.63; p<0.001), Medicare and Medicaid beneficiaries, as well as other self-paid or government subsidy dependents (AOR 0.71, 0.14, and 0.09, respectively; p<0.001 for all) were less likely to access an RARP-performing hospital, compared with privately paid patients. Additionally, compared with patients who lived in the lowest median household income area, those residing in a higher income area were more likely to access a RARP-performing hospital (AOR 1.17, 1.26, and 1.90 by ascending order of income quartile; p=0.02, <0.001 and <0.001, respectively). Compared with patients without comorbidities, patients who had a higher number of comorbidities were less likely to access a RARP-performing hospital (AOR 0.54, p<0.001). Relative to metro residence, non-metro residence was associated with lower odds of accessing an RARP-performing hospital (AOR 0.28, p<0.001). At the hospital level, government hospitals (AOR 1.23, p=0.003), teaching hospitals (AOR 4.75, p<0.001), and larger hospitals with 400 beds or more (AOR 7.06, p<0.001) were more likely to be an RARP-performing hospital compared with not-for-profit, non-teaching, and smaller hospitals with 399 beds or less.
Whereas model 1 analysed the likelihood of patients with PC receiving RP at an RARP-performing versus a non-RARP performing hospital, model 2 examined patients’ likelihood of receiving robotic surgery within RARP-performing hospitals. Thus, model 2 identifies socioeconomic, payer status and other factors that may predict receiving RARP versus ORP or LRP. The sample for model 2 consisted of 14 679 patients from 73 hospitals. Hospitals included in model 2 performed at least one RARP during the study period. After controlling for selected patient demographics and hospital characteristics, within-hospital analysis revealed that age, race/ethnicity and income (except for the third quartile, ie, the middle-high income group) were no longer significant predictors of receiving RARP. However, we found that significantly and consistently, Medicaid beneficiaries had 58% lower adjusted odds of receiving RARP, compared with those with private insurance (AOR 0.42; p<0.001). Having two or more comorbidities was associated with a lower likelihood of receiving RARP relative to patients with no comorbidities (AOR 0.80, p<0.001). Investor-owned and government-owned hospitals were 60% and 49% less likely, respectively, to perform RARP compared with not-for-profit hospitals (AOR 0.40 and 0.51, respectively, p<0.001 for both). Teaching hospitals were more likely than non-teaching hospitals to employ robotic surgery in treating patients with PC (OR 1.65, p<0.001). Interestingly, we found that larger hospitals (400 and more beds), relative to their smaller counterparts, were negatively associated with the likelihood of performing RARP (OR 0.53, p<0.001).
We performed sensitivity analysis by hospital surgery volume to test whether results systematically varied between high-volume and low-volume hospitals (table 4). Seventy-three RARP-performing hospitals were categorised into high volume if they performed more than 500 RARPs, medium volume if they performed between 200 and 499 RARPs, and low-volume if they performed fewer than 200 RARPs during the study period. We found a significantly lower likelihood of undergoing RARP by Medicaid beneficiaries compared with those privately insured, only within high-volume hospitals and medium-volume hospitals (AOR 0.09 and 0.51, p<0.001 and p<0.03, respectively).
By using SID-AHA merged data from 2009 to 2011 in California, we examined patient and hospital characteristics associated with (1) accessing an RARP-performing versus non-RARP-performing hospital and (2) patient receipt of RARP within hospitals performing RARP. Despite the rapid increase in the use of RARP during the last decade, our analysis showed that potential benefits from this advanced surgical technology were not equally distributed among patient subgroups in California at either the hospital level or the individual patient level. For example, Hispanic ethnicity, Medicare/Medicaid insurance, low socioeconomic status and non-metro residence status were negatively associated with access to an RARP-performing hospital. An analysis of RARP-performing hospitals further suggested that Medicaid patients were less likely to receive RARP than were privately insured patients, even after adjusting for selected confounding factors.
Our study findings highlight that racial and socioeconomic disparities exist in accessing an RARP-performing hospital, after controlling for selected patient and hospital characteristics. We defined an RARP-performing hospital as a hospital which performed at least one RARP from 2009 to 2011, using all inpatient data available in the California SID database. In our study, RARP-performing hospitals compared with non-RARP-performing hospitals were generally larger, more likely to be not-for-profit, have teaching status, and be located in an urban area. These findings are consistent with previous cancer care studies of the characteristics of high surgical volume hospitals.13–14 ,21–23 Moreover, RP markets are becoming more centralised, by regionalising RP treatments within limited geographic areas.24 The regionalisation of RP hospitals has increased patient's mean travel time to health facilities,15 which may further exacerbate disparities in access to care for minorities and lower income patients, who may have transportation limitations. To the best of our knowledge, previous studies have not examined the centralisation of care in California. Our sensitivity analysis by volume showed that only six hospitals were providing more than 500 RARP cases during the 3-year study period. More detailed studies are needed to understand the impact of centralisation of RP services and the association with access issues for minority populations.
Different patterns of patient referral among racial and socioeconomic subgroups can be another factor affecting differential access. Selective referral to high-volume urologists or hospitals has been advocated to improve quality of surgical care.16 However, recent studies found that racial minorities and patients with lower socioeconomic status were less likely to have access to high-volume facilities23 or hospitals with advanced technology.25 A recent study revealed that African-American men with PC were less likely to be treated by high-volume urologists even though both African-American and Caucasian men had an equal chance of being diagnosed by high-volume urologists.14 More research is needed to understand mechanisms of referral patterns of Hispanics and their association with lower socioeconomic status in accessing an RARP-performing hospital.
We further examined within-hospital variation in the utilisation of RARP across patient subgroups to identify factors that are predictive of use of RARP versus non-RARP procedures. Compared to privately insured patients, we found Medicaid patients to have substantially lower adjusted odds of receiving RARP within an RARP-performing hospital. This disparity was further magnified in that Medicaid beneficiaries were less likely to have access to an RARP-performing hospital in the first place. Furthermore, the differential likelihood of receiving RARP by payer type was largest in high-RARP-volume hospitals. Our results have important implications in the context of the Affordable Care Act (ACA) because many states, including California, have expanded the eligibility for Medicaid under the ACA. Consequently, we expect that disparities in both access to an RARP-performing hospital and receipt of RARP within an RARP-performing hospital may increase further as the number of Medicaid enrollees grows over time.
Differential use of RARP by payer type could be related to quality of care for patients unable to access RARP. A recent study investigating 61 167 RP cases in the USA during 2003–2007 showed that patients with Medicaid and Medicare had higher rates of blood transfusion, greater overall postoperative complications, longer hospital stays, and higher in-hospital mortality compared to those with private insurance.12 Although the authors did not distinguish between robotic versus non-robotic surgery in their study, our study found that private insurance status is associated with higher levels of utilisation of robotic surgery for RP patients, consistent with the previous study.14 Therefore, Medicaid patients, who had relatively lower odds of receiving RARP in our study, may have worse post-treatment outcomes than those with private insurance. Of course, Medicaid or uninsured patients may have higher risks of in-hospital mortality/morbidity and longer hospital stays.12 To answer this question—that is, whether Medicaid patients who receive robotic surgery have better or worse outcomes than Medicaid patients who receive non-robotic surgery—future research should compare outcomes of RARP versus non-RARP stratified by patients’ insurance status, adjusting for confounding factors.
Our study does have a few limitations. First, the study used administrative records of all RP patients for the State of California. Our data lacks preoperative patient characteristics, as well as long-term oncological or functional outcomes, which may partially explain the relationship between patient characteristics and the decision to use RARP versus ORP or LRP. Second, our study did not consider cultural factors associated with different racial/ethnic groups. It is possible that Hispanic patients may have lower preference of seeking ‘high-tech’ care and ended up with having less travel to ‘high-tech’ hospitals when the nearest hospitals do not offer robotic surgery. However, these measures (ie, individual preference or home-to-hospital distance) are not available in our current data, but remains to be explored in future studies. Finally, the generalisability of the study findings may be limited to a single state. California has more than twice the Hispanic population (38%) when compared with the US average (17%).26 This factor may have an effect on our findings of significant racial differences between Hispanics and non-Hispanic whites. Our study findings should be generalised with caution, particularly for those states with higher African-American populations or lower Hispanic populations. Nevertheless, given that California is the most populous state (38 million by a 2014 estimate)26 with a sizable RP population (20 411 cases for a 3-year study period), and a representative RARP rate (67% for 3-year study period), it provided our research team with a very large sample to conduct our analysis. Additionally, to the extent that health disparities in California are presumably more substantial than the national average,27 our data containing all the population-level inpatient records in California may yield more robust inference for local decision-makers. Further research focusing on racial/ethnic disparities in the use of RARP needs to be conducted in other states to improve the generalisability of these study findings.
Our study findings have significant clinical implications. The lack of access to an RARP hospital or RARP procedures within RARP-performing hospital may imply less ideal care for the Hispanic minority and patients with lower socioeconomic status, if benefit of RARP exceeds LRP or ORP. Currently, no definitive evidence supports a clinical advantage of the use of RARP compared with open or laparoscopic surgery. Recent studies have shown that RARP has similar or only marginal improvements in outcomes.6 ,7 ,28–30 Additionally, research findings about the cost-effectiveness of RARP are inconclusive.30–33 Randomised clinical trials (RCT) are often recommended as powerful tools to provide the highest level of scientific evidence of cause-and-effect relationship between an intervention and outcomes. However, conducting RCTs can be challenging given that at least 85% of the RP cases are now robotic in the USA.2 Diverse, innovative approaches with advanced statistical methodologies and longitudinal functional outcomes will be needed to provide more robust evidence of the potential benefits of RARP versus ORP or LRP.
Despite the rapid increase in the use of RARP in the past decade, our analysis showed that this growth may not have been equally distributed throughout the patient population. Hispanic ethnicity, Medicare/Medicaid insurance, low socioeconomic status and non-metro location were negatively associated with access to an RARP-performing hospital. Even within RARP-performing hospitals, Medicaid patients are less likely to receive RARP versus other non-robotic procedures than are privately insured patients, after adjusting for selected confounding factors. Our study results suggest that both access to an RARP-performing hospital and differential access to RARP within an RARP-performing hospital are important sources of potential future disparities, particularly for Medicaid patients in high-RARP-volume hospitals.
The authors would like to thank Dr Onook Oh, Dr Hongmei Wang and Dr Mohammad Siahpush for their inspiration, support and encouragement for this study.
This web only file has been produced by the BMJ Publishing Group from an electronic file supplied by the author(s) and has not been edited for content.
Files in this Data Supplement:
- Data supplement 1 - Online supplement
Contributors JK conceptualised and designed the study, conducted data analysis and interpreted the results, drafted the manuscript and edited the manuscript for important content. WE assisted in the data management and analysis, conducted literature review and edited the manuscript for important content. FW provided the data, interpreted the results and edited the manuscript for important content. DS, DO and MM edited the manuscripts for important content. L-WC assisted in the conceptualisation and the design of the study, and edited the manuscript for important content.
Funding This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.
Competing interests None declared.
Ethics approval The University of Nebraska Medical Center Internal Review Board determined that the study does not constitute human subject research due to the use of de-identified patient records of publicly available secondary data.
Provenance and peer review Not commissioned; externally peer reviewed.
Data sharing statement The study used secondary data which is publicly available.